. Author manuscript; available in PMC: 2022 Jun 4.

Published in final edited form as: J Med Chem. 2022 Feb 15;65(4):3404–3419. doi: 10.1021/acs.jmedchem.1c01934

Table 5.

PK Parameters of Compound 23 (DX3-213B) in Plasma Following IV and PO Administration

Route	Dose	C₀	AUC(0-tldc)	AUC(0-inf)	CL	Vss	Bioavailability	t_1/2
Unit	mg/kg	ng/mL	nM:h	nM:h	mL/min/kg	L/kg	%	h
IV	2	354.0	650.0	657.0	106.0	5.2	/	1.42
PO	10	/	368.1	417.1	834.8	/	11.3	3.06

PK parameters were estimated using non-compartmental analysis with Phoenix/WINONLIN.

C₀ = Initial concentration, AUC (0-tldc) = Area under the concentration-time curve from time zero to time of last detectable concentration, AUC (0-inf) = Area under the concentration-time curve from time zero to infinite, CL = Systemic clearance, Vss: Volume of distribution at steady state, Bioavailability = (AUC_T×Dose_iv) / (AUC_iv×Dose_T) ×100%, Terminal elimination half-life (t½) was calculated based on data points (>= 3) in the terminal phase.